Page 337 - Read Online

Monks et al. J Cancer Metastasis Treat 2019;5:24 I http://dx.doi.org/10.20517/2394-4722.2018.79 Page 23 of 23

194. Sun Y, Zang Z, Zhong L, Wu M, Su Q, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high
throughput assay. PLoS One 2013;8:e63354.
195. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life
in obesity. Nature 2013;503:493-9.
196. Yousefnia S, Momenzadeh S, Seyed Forootan F, Ghaedi K, Nasr Esfahani MH. The influence of peroxisome proliferator-activated receptor
γ (PPARγ) ligands on cancer cell tumorigenicity. Gene 2018;649:14-22.
197. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. PPARgamma ligands increase expression and plasma concentrations of
adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
198. Murakami H, Ono A, Takahashi T, Onozawa Y, Tsushima T, et al. Phase I study of Efatutazone, an oral PPARγ agonist, in patients with
metastatic solid tumors. Anticancer Res 2014;34:5133-41.
199. Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, et al. Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated
receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Invest New
Drugs 2014;32:473-80.
200. Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, et al. Efatutazone, an oral PPAR-γ agonist, in combination with
paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab 2013;98:2392-400.
201. Boucher E, Davidenko I, Hadler D, Roemeling R von, Aprile G. PD-0008 * a randomized, placebo-controlled, phase 2 study of efatutazone
maintenance therapy in patients with advanced colorectal cancer who have achieved disease control following first-line chemotherapy. Ann
Oncol 2014;25:ii8.
202. Williams R. Discontinued in 2013: oncology drugs. Expert Opin Investig Drugs 2015;24:95-110.
203. Chang S, Lee J, Oh H, Kim U, Ryu B, et al. Troglitazone inhibits the migration and invasion of PC-3 human prostate cancer cells by
upregulating E-cadherin and glutathione peroxidase 3. Oncol Lett 2018;16:5482-8.
204. Hong OY, Youn HJ, Jang HY, Jung SH, Noh EM, et al. Troglitazone inhibits matrix metalloproteinase-9 expression and invasion of breast
cancer cell through a peroxisome proliferator-activated receptor γ-dependent mechanism. J Breast Cancer 2018;21:28.
205. Fujita M, Hasegawa A, Yamamori M, Okamura N. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. J Exp Clin Cancer
Res 2017;36:91.
206. Nazim U, Moon JH, Lee YJ, Seol JW, Park SY. PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced
apoptosis via autophagy flux. Oncotarget 2017;8:26819-31.
207. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma
ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003;79:391-7.
208. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, et al. A phase II study of troglitazone, an activator of the PPARgamma
receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002;8:395-9.
209. Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARγ-independent antitumor effects of thiazolidinediones. Cancer Lett 2009;276:119-24.
210. Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, et al. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-
activated receptor-gamma agonist, in obese diabetic rodent models. J Pharmacol Sci 2009;111:155-66.
211. Hiuge-Shimizu A, Maeda N, Hirata A, Nakatsuji H, Nakamura K, et al. Dynamic changes of adiponectin and S100A8 levels by the selective
peroxisome proliferator-activated receptor-γ agonist rivoglitazone. Arterioscler Thromb Vasc Biol 2011;31:792-9.
212. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J
Cancer 2003;89:1409-12.
213. Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, et al. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort
study. Cerebrovasc Dis 2013;36:145-51.
214. Holland WL, Scherer PE. Cell Biology. Ronning after the adiponectin receptors. Science 2013;342:1460-1.
215. Muppala S, Konduru SKP, Merchant N, Ramsoondar J, Rampersad CK, et al. Adiponectin: its role in obesity-associated colon and prostate
cancers. Crit Rev Oncol Hematol 2017;116:125-33.
216. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91:258S-261S.
217. Lee SH, Hong HR, Han TK, Kang HS. Aerobic training increases the expression of adiponectin receptor genes in the peripheral blood
mononuclear cells of young men. Biol Sport 2015;32:181-6.
218. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
219. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and
plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459-69.